Speakers

Adam Vas

Adam Vas

Prof. Adam Vas was born on April 19th, 1952 in Budapest, Hungary. He graduated from the Semmelweis Medical University and specialized in internal medicine and clinical pharmacology. Dr. Vas spent 6 months at the University Berne, Department of Clinical Pharmacology (1986-1987; Prof. Adrian Küpfer) and 3 months at the University of Newcastle upon Tyne, Pharmacogenetics Research Unit (1991; Prof. Jeff Idle) on grants. He went on study visits to the Karolinska Institutet, Dept. Clinical Neuroscience Stockholm several times (2000-2010; Prof. Balázs Gulyás) doing PET studies in the neurological field. Dr. Vas got his PhD degree in 1990. He became a Professor in medicine to the 1.s Dept. of Medicine at the Szeged University in 2006. His teaching activities are in the field of clinical pharmacology. Dr. Vas is a member of several Hungarian and international societies. He is the Treasurer and Incoming President of the Hungarian Society for Experimental and Clinical Pharmacology, Honorary President and former Treasurer of the European Society for Clinical Pharmacology and Therapeutics, Head of the Scientific-Engineering Committe of the Hungarian Pharmaceutical Manufacturers’ Association and member of the EU IMI Scientific Committee among other positions. Dr.Vas is also heading the Hungarian National Technological Platform for Innovativ Drug Research. Dr. Vas joined Gedeon Richter Plc., Budapest in 1993. He is presently the Senior Research Adviser to the CEO. He published over 80 papers.


Erik Lund

Erik Lund

Dr. Erik Lund is MSD’s Licensing Ambassador to the Nordic Countries, Baltic States, Eastern European Union, Austria, Greece and Turkey. As such he is working with local life science industries and academic institutions to forge partnerships with MSD. During his career within MSD Licensing, Dr. Lund has been the scientific lead for executed partnerships ranging from basic research collaborations to licensing of Phase III compounds. In his prior scientific career with MSD and Academia Dr. Lund has authored >35 original research publications in peer reviewed scientific journals with a particular focus on the investigation of the formation of and biological significance of oxysterols. Dr. Lund is a graduate of Royal Institute of Technology and of Karolinska Institute, both of Stockholm, Sweden, and did postdoctoral research at University of Texas Southwestern Medical Center at Dallas, TX before joining MSD in 2000.


Mariusz Jarzębowski

Mariusz Jarzębowski

Mariusz Jarzębowski Entrepreneur and expert-generalist who has worked in the high-tech industry in the United States, Austria and Germany. Before coming back to Europe, Mariusz worked in Silicon Valley at NeXT Software and Apple Computer run by Steve Jobs. In Poland he was involved in establishing and running new ventures. Also, Mariusz worked at a venture capital and private equity firm where he continued to be involved in new venture development, and served on the Board of Directors and the Advisory Board. At Microsoft, as a specialist in competitive strategy and new markets, Mariusz helped companies create new sources of growth like entrepreneurs, and learn from start-ups. He is a mentor to start-ups. Mariusz wrote „The Gravity of Silicon Valley” for THINKTANK Magazine. He is a speaker on innovation and entrepreneurship. Holds MBA and MS degrees from Warsaw University of Technology Business School, in partnership with London Business School, where he served on the School’s Council and continues to serve on the Advisory Board. For more, visit www.mariuszjarzebowski.com.


Jan Kowalczyk

Jan Kowalczyk

Jan Kowalczyk is a CEO of Banner Group and specializes in strategy consulting, capital raising and interim management. Prior to launching Banner in 2004 he worked in the private equity industry and managed operating companies in Central and Western Europe.


Antal Ördögh

Antal Ördögh

Antal Ördögh currently holds the position of Executive Director at the Hungarian Biotechnology Association.

Between 2005 and 2008 he occupied the position of Project Manager at DARFÜ (South-Plain Regional Development Agency). During the time spent there he was part of the international work group of the region and he has participated in a number of international projects – chiefly involving other members of the European Union. With his work he contributed to the sustainable economical development of the region (INTERREG III C projects) and to the promotion of the regional technological transfer (FP 6)

Previously he worked at Szatymaz Local Government as Project Manager. His main tasks were managing tenders involving overall development of the settlement.

Between 2002 and 2004 he was working as a Project Manager in the micro-regional office in Mórahalom, where he dealt with projects enhancing the economic development of settlements of the micro region. In the absence of the CEO, Mr Ordogh attended also the management tasks of the office.

In 2004 he was given the opportunity to participate in the Minnesota Agricultural Student Trainee program (MAST) as an exchange student. During the time spent in the United States he perfected his knowledge of English language and he also established good relations with the other participants of the program.Antal Ordogh earned his degree in agricultural engineering at the Szent Istvan University in Gödöllő, Hungary. His Thesis and chosen field was rural and spatial development and also professional consulting.


Allan Marchington

Allan Marchington

Allan Marchington is responsible for Life Science investments at Apposite Capital. Apposite is based in London and invests on a global basis in healthcare and related areas, including both healthcare services and life sciences. Apposite has over $200M under management and typically leads investments rounds with between $1m to $20m investments. Allan is a Board member of Ambit Biosciences Inc., Ambrx Inc, and Sotera Wireless Inc.Allan was formerly a medicinal chemist at Pfizer, Sandwich UK. In 1997 he left Pfizer to start his own company Cambridge Discovery Chemistry, which grew to over 130 staff and was a leading medicinal chemistry company service provider. In July 2000 Millennium Pharmaceuticals Inc. bought the company and Allan moved to the USA to join the Millennium Management team, responsible for all their technology investments and Chairman of the European division.In 2003, he returned to the UK and after a brief period at Abingworth Management he joined the founding team at Apposite Capital.


Mariusz Olejniczak

Mariusz Olejniczak

Mariusz Olejniczak graduated as an MSc. Eng. in Biotechnology from University of Life Sciences in Poznan, Poland and is General Manager and Chief Operating Officer – Late Stage Projects for Assign Group Poland. He started his career in clinical research organizations in 2003 after working in the medical device industry. Prior to this he worked in the Bioengineering Laboratory of the Foundation of Development in Cardiac Surgery NZOZ FRK Homograft. During this time he was involved in tissue engineering, tissue banking and medical device research and commercial projects. One of his primary interests are advanced therapy and biological products. As General Manager of Assign Group, Poland, Mariusz meets his clients’ individual requirements for all pharmaceutical development needs whether locally, regionally or global.


Paweł Przewięźlikowski

Paweł Przewięźlikowski

Paweł Przewięźlikowski co-founded Selvita in 2007 and is the Chief Executive Officer of the company. Before Selvita he spent 12 years managing high technology companies, meeting customers’ expectations and creating significant shareholder value. From 1994 to 2007 he worked at ComArch – a Polish information technology company. As board member of the company since 1996, he took part in the organic transformation of a university spin-off to the largest IT company in Poland, employing over 2 700 people. During his time at ComArch in 1999-2000 he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. He is also the Chief Executive of BioCentrum, Selvita’s daughter company.


Tara Sherbrooke

Tara Sherbrooke

Tara Sherbrooke is an commercial intellectual property lawyer with 7 years post qualification experience, much of it working with clients in the Life Sciences, Pharmaceutical and Technology sectors. Her experience covers advising in relation to strategic alliances and licensing, commercial and corporate transactions as well as a range of distinct Intellectual Property issues. Tara was previously an associate with US firm Morrison & Foerster LLP and, more recently, with corporate finance advisers Europa Partners. She trained as a solicitor at Norton Rose and has an undergraduate a degree in Cellular and Molecular Pathology.Osborne Clarke considers itself an “insider” in the life sciences sector because of our in-depth understanding of the scientific and business issues life sciences companies face. Osborne Clarke has expertise in private equity, M&A, intellectual property (contentious and non-contentious), regulatory, competition and commercial law and not only does the team understand the technical and legal issues, but several members also have advanced scientific qualifications and industry experience. Osborne Clarke’s Life Sciences sector team advises a range of clients including Takeda, Mitsubishi Pharma Europe and Quintiles on a range of matters.


Leszek Grabarczyk

Leszek Grabarczyk

Leszek Grabarczyk Since April 2011 Deputy Director of the National Centre for Research and Development – reshaped governmental agency playing the main role in funding applied research and supporting commercialisation of research results.

January 2009 – March 2011: director of the Department for Research Applications and Innovation, Ministry of Science and Higher Education, Warsaw (main responsibilities: funding of projects and infrastructures for R&D within operational programmes Innovative Economy and Human Capital, elaboration and implementation of other programmes supporting innovation, coordination and monitoring of activities of other institutions engaged in support of R&D and innovation).

July 2007 – December 2008: deputy director of the National Centre for Research and Development – NCRD (governmental agency funding R&D, established 1 July 2007). 2004-2007: in the Polish Ministry of Science and Higher Education, Department of Science Strategy and Development; engaged inter alia in preparation of legal framework for NCRD, operational programmes Innovative Economy and Human Capital, elaboration and implementation of the largest governmental programme funding R&D and innovative activities – “Technology Initiative”.

Graduated from the National School of Public Administration, Warsaw.


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bioentrepreneur who has worked in the industry for approaching two decades. Roland has held a number of operational roles including most recently Chief Executive Officer and a founder of Lectus Therapeutics Limited (investor exit via asset sale to UCB in Q4, 2011), Chief Executive Officer and co-founder of Sense Proteomic Limited (trade sale to Procognia Limited in Q1, 2003). In the mid 1990s Roland worked with Oxford Molecular PLC on their cornerstone deal he negotiated with Yamanouchi Pharmaceutical Co., Ltd. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing and commercialisation of technology. In the past Roland ran a Research Groups at the University of Oxford and University of Bristol where subsequently he was a Visiting Industrial Professor. He has published and patented in the field of ion channel physiology and pharmacology. Roland has served on the boards of a number of companies including the Bio-Industry Association in the UK. He remains a director of Lectus Therapeutics Limited and is presently non-executive director of London Genetics Limited which operates in the personalised medicine space, Chief Strategy Officer of BTM Mazowsze Sp. z o. o. a company set up to commercialize innovation emerging from the leading life science research institutions in Warsaw.


Oliver Murphy

Oliver Murphy

Oliver Murphy Partner Transaction Advisory ServicesOliver is a graduate of the University of Manchester in Economics and Government. He speaks fluent Polish.

Oliver has has a wide range of corporate finance, due diligence and restructuring and integration experience within both the UK and Poland and specialises in cross-border transaction support engagements comprising large multi-disciplinary, multinational teams.


Agnieszka Deeg

Agnieszka Deeg

Agnieszka Deeg is in charge of Life Science and Healthcare. She has extensive experience in working with companies from the pharmaceutical and medical sector, regarding various aspects of their activity including: patent disputes, acquiring rights to products, distribution and service agreements, parallel trade issues, refunds and pricing, and product registration. She conducts a number of proceedings regarding classification of dietry supplements, and provides advice for clinical trials as well as advertising and manufacturing of medicinal products. She was an advisor during the preparation and adoption of the Code of Ethics of Innovative Pharmaceutical Companies

In her work, she deals with clients from the pharmaceutical and medical sector and private equity transactions. She has participated in a number of significant projects, amongst others acquisitions of stock listed companies and venture capital investments. She has represented international financial institutions upon the acquisition of Polish banks and leasing companies, and LBO & MBO transactions, and has represented financial institutions and lenders upon issuance of debt securities, granting finance, and financial lease transactions.

She has been a speaker during numerous pharmaceutical conferences for many years. She is recommended by the Chambers and Partners as a specialist in the area of pharmaceutical law in Poland. She graduated from the Warsaw University Faculty of Law and she is a doctoral student in the Polish Academy of Sciences.


Martin Oxley

Martin Oxley

Martin Oxley is Country Head of UK Trade and Investment at the British Embassy in Warsaw. Prior to that he was CEO of the BPCC which under his leadership grew to be the leading international business networking organization in Poland. Over the course of the last 15 years he has held CEO and Board positions in the market leading global and regional pharmaceutical companies in Central Europe. He retains a strong interest in healthcare, life sciences and enterprise. He serves on the advisory boards of a number of youth enterprise networks. He is a recognized international expert and speaker on Poland.


Darrin M Disley

Darrin M Disley

Dr Darrin M Disley is the CEO of Horizon Discovery Limited, a world-leading translational genomics company and one of the fastest growing Biotech companies in Europe. At Horizon, he is responsible for corporate development, business strategy and investor relations; and since October 2007 has overseen four years of 100% top line revenue growth and a 364% increase in exports which make-up 90% of all revenues. These achievements have led to the company being recently named the East of England’s Business of the Year and being conferred with a Queens Award for Enterprise in International Trade.Darrin is a parallel business entrepreneur and has been involved in the start-up and growth of ten high-tech business ventures. He has raised in excess of $80M of business financing from Angel, Corporate and Venture and has closed in excess of $150M in business development deals in the Life Science sector.He is an experienced general manager with a track-record for raising investment for and managing the growth of early-stage technology companies. Darrin holds a PhD in Biotechnology from the University of Cambridge; has been the author of six papers, 7 patent applications and 36 conference abstracts and; has been an advisor on biotech commercialisation strategies to key technology centres in Europe, USA, India and Africa.Dr Disley is an avid supporter of “ethical entrepreneurship” and supports numerous academic, business plan competition and mentoring programs in the UK with financial and practical support.


Angelo De Rosa

Angelo De Rosa

Angelo De Rosa is head of Strategy and Business Development at Medtronic for Europe, Middle East, Africa and Canada (EMEAC). Angelo has over 17 years of international experience in the Healthcare market, covering General Management, Business Development, Sales and Marketing, Clinical responsibilities in diversified geographic areas. He is also an entrepreneur, in 2010 he founded a start-up company called NayaMed. Passionate for business model innovation and disruptive healthcare delivery models. Member of the International Grants Committee for the Medtronic Foundation and active speaker in the MedTech area at European level.

Angelo received his Biomedical Engineer Degree from the University of Pisa, Italy. He holds an MBA from Politecnico di Milano in Italy. He attended numerous management programs, such as the High Performance Leadership Program at IMD in Lausanne, Switzerland.


Charles Bridgen

Charles Bridgen

Charles Bridgen is the European Business Development & Licensing Director for Amgen International. In this role he has supported many of Amgen’s recent global M&A transactions including the $1.16B acquisition of Micromet, a biotechnology company founded in Germany and the acquisition of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. He is also responsible for external R&D partnerships in Europe including Eastern Europe and Russia.Having joined Amgen in 2004 as Therapeutic Area Lead for Oncology, his most recent role was Executive Medical Director for the UK & Ireland where he led Amgen’s R&D efforts in this region. Prior to joining Amgen, Charles worked for Eli Lilly & Company as a Clinical Research Physician. Before joining industry, Charles trained as a surgeon in the UK’s National Health Service working in academic teaching hospitals in London. He is a Fellow of the Royal College of Surgeons in England, a Member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and holds an MBA from Columbia & London Business Schools.


Harald Berninger

Harald Berninger

Harald presently holds the position of Market Development Manager for personalized healthcare (PHC) at QIAGEN where his main responsibility is to develop and expand companion diagnostics business involving all sales channels in Central Europe. He is also leader of the European Business Team PHC implementing Pan-European tactics in various countries. Previously at QIAGEN he has held the position of Director of Life Science Asia and Regional Export Manager, and was in the past Vice President of Sales and Marketing at Kreatech Diagnostics. Harald was educated at the University of Tübingen, Germany and the University of California where he obtained his Master of Science.


Dayle Hogg

Dayle Hogg

Dayle Hogg joined the Healthcare Ventures team in June 2011. Previously, Dayle worked in the biotechnology sector and has more than 10 years’ experience of drug discovery and development across multiple therapeutic fields including, pain, urology and immune disorders. Most recently Dayle was Commercial Vice President of Lectus Therapeutics Ltd, an ion channel drug discovery company, where he was responsible for business development activities, the closure of a number of successful licensing and divestment transactions and involved in closing a number of financing rounds. Dayle has DPhil in Pharmacology from the University of Oxford, where his research focused on voltage-gated ion channels in the pulmonary circulation.


Andy Merritt

Andy Merritt

Dr Andy Merritt is Associate Director of Chemistry at the MRCT Centre for Therapeutics Discovery (CTD). The CTD is the drug discovery arm of the Medical Research Council Technology group, which looks to develop innovative drug screens emerging out of ground breaking MRC research and subsequently prosecutes drug discovery programmes. Screening of a carefully constructed library provides good medicinal chemistry starting points, which in combination with structural information on targets can be utilized in medicinal chemistry strategies.Previously Andy was a Director of Discovery Medicinal Chemistry at GlaxoSmithKline, a role which encompassed global responsibility for outsource support for lead discovery chemistry and for the provision of molecular tools for target validation. He was at the forefront of the development and application of combinatorial chemistry and technologies to drug discovery, high throughput screening and hit to lead development since the initiation of the approach in the early 1990s. The use of outsourced resources to support early stage drug discovery in GSK was developed within his teams, building an operation spanning the globe and encompassing all aspects of chemistry services for early drug discovery. Dr Merritt joined the former Glaxo organization in 1988 following postdoctoral studies in the US, and initially worked on oncology and pain drug discovery programs.Andy sits on the RSC Chemical Biology interface Forum Executive and the Chemistry World editorial board. He sat on the Royal Society higher education working group which published 2 reports on STEM subject provision in 2006 and 2008. He has been a regular undergraduate lecturer in pharmaceutical medicine at Imperial College, Warwick and Sussex universities.


Katie Ellias

Katie Ellias

Katie Ellias is on the life sciences investment team at Sofinnova Partners, where she focuses on investments in the medical device sector. She acts as a Board Observer for Stentys, SA and MD Start, a medical device incubator co-founded by Medtronic and Sofinnova.Katie was previously with Medtronic Inc, where she most recently led the European Coronary team as the Group Marketing Manager and interim Business Director, supporting the $500M product portfolio by defining and executing marketing and sales strategies which have positioned Medtronic as a leading company in the interventional cardiology space. Additionally, Katie initiated and led the Medtronic EUreka program (www.MedtronicEUreka.com), an international, cross-business innovation initiative that generates 10,000 website visits monthly and resulted in over 200 European inventors’ annually approaching Medtronic with their ideas for possible partnership opportunities with Medtronic and MD Start. Katie worked initially in Business Development for Medtronic’s Cardiac Surgery division in Minneapolis, where she coordinated the Corevalve and Ventor transcatheter value acquisitions, efforts in surgical heart valves, and atrial fibrillation technologies. She also conducted marketing and business development efforts in the CRM, Dental implants, and Gastrology and Urology fields.Katie holds an MBA in Healthcare Management from the Wharton School and a BA in International Relations and Political Science from Yale University. Katie has worked as was a contract negotiator for Partners Healthcare System in Boston working on healthcare policy and healthcare finance for the region’s largest hospital network. She began her career as a consultant with McKinsey & Company strategy consulting in Boston.


Robert Mołdach

Robert Mołdach

Robert Mołdach, leading expert and owner at eFabrica consulting practice, supports private enterprises and investors operating in the Polish healthcare sector in scope of strategic market assessment, business development, operation excellence and legislation monitoring.

Robert is recognized for his public engagement in the social dialogue and education. Acting on behalf of the Employers of Poland, he speaks to the Parliamentary Healthcare Commission, the Tripartite Commission for Social and Economic Affairs and other bodies, rising key challenges of the public health system. He is also the author of the Healthcare Management Practice MBA program at Lazarski University in Warsaw, teaching the corporate culture, IT governance and the social dialogue.

In the past, Robert developed an outstanding orthopedic hospital Carolina Medical Center. Before that he worked in financial and ICT sectors performing key roles in the European and Polish business development.

Robert received masters and engineer degree in advances of technology from the Warsaw Technical University (MEL), PhD in mathematical modeling from the Polish Academy of Sciences (IPPT) and CMPE nomination from the American College of Medical Practice Executives (MGMA). Privately, Robert is a husband and father of two adult children, an airplane pilot and a delegate of the Aeroclub of Poland.


Michał Bańka

Michał Bańka

Michał Bańka works at the Ministry of Economy to manage and mediate implementation of several EU funded programs. Since 2006 his responsibilities have included running the financial departments of three Programs: (1) Improving the Competitiveness of Enterprises, (2) Innovative Economy and (3) Infrastructure and Environment. He has held the positions of Deputy Director, and from 2012 Director of the Department of Business Environment Institution Support of the Polish Agency for Enterprise Development. His responsibilities include: (1) Providing support for business incubators in finding innovative ideas and capital input for „Start-ups”, (2) Support of the ‚Business Angels’ Network, (3) Support for Business Environment Institutions, (4) Financing of advisory services that are necessary to attract external investors. His business career is combined with an academic role involving teaching at the Faculty of Political Science at Warsaw University. He is the project manager and general executive of R & D projects of the Ministry of Science and Higher Education and author and co-author of several monographs and scientific articles.


Martin Bonde

Martin Bonde

Martin Bonde, Ph.D, B.Comm. is CEO of Epitherapeutics ApS (www.epitherapeutics.dk). He is a serial entrepreneur who has founded and managed several companies in Denmark and the US including Aros Pharma ApS, NatImmune A/S, Combio A/S, CelTor Inc., Torsana Biosensor and Osteometer Biotech. Martin has fronted several successful exits over the last decade including NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc. as well as executing several significant out-licensing deals, acquisitions, in-licensing deals and collaborations. He is engaged as board member in Orphazyme ApS (www.orphazyme.com) (Chairman) and is Chairman of the Danish Association of Biotech Companies (www.danskbiotek.dk).


Jeffery Grady

Jeffery Grady

A US citizen with over 25 years of experience in private equity fund formation and management, venture capital, investment banking, hands-on company turnaround in Central Europe (as CEO), Russia, Central Asia and Israel. Mr. Grady assisted in the formation of an Israeli High-Tech Fund and sat on the Investment Committee of that fund. Mr. Grady has also launched several of his own start-up companies with international investors and international funding, successfully exiting these investments to acquirers. He has also been an ‘angel investor’ in early stage companies in Poland and the US. He has a B.A. and M.A. from the University of Virginia and an MBA from Yale University. Mr. Grady currently splits time between the US, Poland and Germany, primarily investing in early-stage companies.


Lukasz Kalinowski

Lukasz Kalinowski

Lukasz Kalinowski has worked with ADAMED since 2009. Presently he heads the Company’s Drug Discovery unit where he is responsible for strategy execution that includes overseeing all of ADAMED innovative drugs research and development activities as well as business development and partnering. Prior to joining ADAMED, he worked for international professional services firms providing strategy and management consulting for clients from the CEE region. Lukasz graduated from Technical University of Denmark and Warsaw University of Technology. He also attended professional education courses at MIT.


Pawel Wielgus

Pawel Wielgus

Pawel Wielgus, PhD currently holds a position of Key Account Manager in Life Science Department of Wroclaw Research Centre EIT+ Ltd. where he is mainly responsible for commercialization field. He obtained his MSc degree in biotechnology at Wroclaw University of Technology (WUT, Poland). He was also awarded a PhD degree at WUT, for which he studied theoretical and computational chemistry. During his PhD program he was awarded a prestigious scholarship at the Max Planck Institute for Chemical Physics of Solids (Dresden, Germany) as a part of 3-year postgraduate International Max Planck Research School program. Pawel also completed postgraduate financial studies at Wroclaw University of Economy. Due to his interest in economy and capital market for the last few years he worked in Polish Association of Individual Investors, finally as a Head of Legal Affairs Department. During that time he used to be a member of Supervisory Board of two public companies listed on Warsaw Stock Exchange as well as of several start-up companies.


Marcin Tobor

Marcin Tobor

Marcin Tobor – Investment Manager

He joined KFK in December 2011 and currently is responsible for building the portfolio and supervising the already existing funds.

Prior to this for seven years he had worked in corporate finance and private equity sector in France. He began his professional career with a publicly traded company Buffalo Grill SA as financial analyst. He co-created M&A department in Novasep, where he was responsible for, among others things, screening, evaluation, modeling of potential projects, mergers and acquisitions in the pharmaceutical and bio-tech industries and PMI of newly acquired companies. In next years, he was involved in creating private equity fund LT Capital SA, where he worked on investment projects in the EEC sector (energy, environment, cleantech).

At the Fund’s level, Marcin was engaged in managing restructuring and reorganization projects of portfolio companies as an Interim Manager. Currently, he is a member of the supervisory board of a company operating in cleantech industry – NrGaia SAS.

Marcin graduated from University of Economics in Katowice (former Karol Adamiecki Academy). He was socially engaged in academic as a member and president of the European Centre for Integration Development (ECID).